A Phase 4 interventional study of BIC/LEN FDC and Lenacapavir in HIV-1 Infection, sponsored by Gilead Sciences. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-02.
Sponsored by Gilead Sciences · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this clinical trial is to assess the effectiveness and safety of switching to bictegravir/lenacapavir (BIC/LEN) fixed-dose combination (FDC) compared with continuing stable baseline regimens (SBR) in virologically suppressed people with HIV.
The primary objective of this study is to evaluate the efficacy of switching to BIC/LEN (75/50 mg) fixed-dose combination (FDC) tablets versus continuing their stable baseline regimen (SBR) in virologically suppressed people with HIV.
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
Key Exclusion Criteria:
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will switch to BIC/LEN (75 mg/50mg) FDC tablets once daily starting on Day 1. Participants will receive a 2-day oral loading dose regimen of LEN 600 mg on Days 1 and 2, in addition to the once-daily doses of BIC/LEN FDC starting on Day 1, up to Week 48.
Drug: BIC/LEN FDC · Drug: Lenacapavir
Participants will remain on their existing SBR antiretroviral therapy (ART) regimen from Day 1 through Week 24. At Week 24, they will switch to BIC/LEN (75 mg/50 mg) FDC tablets once daily. At the time of BIC/LEN FDC initiation, participants will receive a 2-day oral loading dose regimen of LEN 600 mg on Day 1 and 2, in addition to the once-daily doses of BIC/LEN FDC starting at the time of switch, up to Week 48.
Drug: BIC/LEN FDC · Drug: Lenacapavir · Drug: SBR
Drug page: Bictegravir
Tablet administered orally
Also known as: Bixlenvo™
Tablet administered orally
Also known as: LEN
SBR will include approved ARTs like: integrase strand-transfer inhibitor (INSTI) + 1 or 2 nucleoside reverse transcriptase inhibitors (NRTIs), excluding bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF), boosted-protease inhibitor (PI) + 2 NRTIs, nonnucleoside reverse transcriptase inhibitor (NNRTI) + 2 NRTIs, or dolutegravir (DTG)/rilpivirine (RPV) or cabotegravir (CAB) + RPV
Proportion of Participants With HIV-1 Ribonucleic Acid (RNA) ≥ 50 Copies/mL at Week 24, as Determined by the United States (US) Food and Drug Administration (FDA) Snapshot Algorithm
Time frame: Week 24
Proportion of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 48 using the US FDA-defined snapshot algorithm
Time frame: Week 48
Proportion of Participants With HIV-1 RNA < 50 Copies/mL at Week 24 Using the US FDA-Defined Snapshot Algorithm
Time frame: Week 24
Proportion of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 Using the US FDA-Defined Snapshot Algorithm
Time frame: Week 48
Change From Baseline in Clusters of Differentiation 4 (CD4) Cell Count at Week 24
Time frame: Baseline, Week 24
Change From Baseline in CD4 Cell Count at Week 48
Time frame: Baseline, Week 48
Percentage of Participants Experiencing Treatment-Emergent Grade 3 or 4 Adverse Events (AEs)
Time frame: First dose date up to Week 48 plus 60 days
Percentage of Participants Experiencing Treatment-Emergent Serious Adverse events (SAEs)
Time frame: First dose date up to Week 48 plus 60 days
Percentage of Participants Experiencing Treatment-Emergent AEs Leading to Discontinuation of Study Drug Through Week 48
Time frame: Up to week 48
Change From Baseline in Patient-Reported Experience and Satisfaction Score, as Assessed by the Questionnaire to Understand the Experience and Satisfaction in a Study in HIV-Treatment (QUEST-HIV-T) at Week 24
The QUEST-HIV-T is a patient-reported outcome (PRO) measure that evaluates experience and satisfaction in a clinical study for HIV. The measure consists of 16-item that is intended to be completed by PWH during an active treatment period using a recall period of "the past 7 days." The QUEST-HIV-T utilizes 5-point verbal descriptor scales (Not at all-Extremely, Very satisfied-Very dissatisfied).
Time frame: Baseline, Week 24
Change From Baseline in Patient-Reported Experience and Satisfaction Score, as Assessed by the Questionnaire to Understand the Experience and Satisfaction in a Study in HIV-Treatment (QUEST-HIV-T) at Week 48
Time frame: Baseline, Week 48
Proportion of Participants Reporting a Preference for BIC/LEN FDC Compared with Previous SBR, as Assessed by the HIV-Treatment Preference Questionnaire (HIV-TPQ) at Week 48
The HIV-Treatment Preference Questionnaire (HIV-TPQ) is a PRO measure designed to evaluate participants' preference between treatment received prior to the study entry and the clinical study intervention. The HIV-TPQ assesses preference across multiple treatment attributes. The overall preference item uses a 3-point categorical response scale (Treatment before the study, Study treatment, No preference). All remaining items use a 5-point verbal descriptor scale (Very much prefer treatment before the study-Very much prefer study intervention).
Time frame: Week 48
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Nov 2026; primary completion for Jul 2028, 20 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Bictegravir · Lenacapavir